Krka, d. d. (LJSE:KRKG)

Market Cap	7.87B +29.9%
Revenue (ttm)	2.11B +7.1%
Net Income	417.65M +9.6%
EPS	13.75 +10.6%
Shares Out	30.28M
PE Ratio	18.92
Forward PE	18.31
Dividend	9.10 (3.50%)
Ex-Dividend Date	Jul 21, 2026

Volume	2,489
Open	260.50
Previous Close	260.00
Day's Range	259.00 - 260.50
52-Week Range	174.00 - 270.00
Beta	0.44
Analysts	Buy
Price Target	242.65 (-6.67%)
Earnings Date	Jul 23, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,300
• Stock Exchange: Ljubljana Stock Exchange
• Ticker Symbol: KRKG

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Analyst Summary

According to 6 analysts, the average rating for KRKG stock is "Buy." The 12-month stock price target is €242.65, which is a decrease of -6.67% from the latest price.

Price Target

€242.65

(-6.67% downside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error